# Evidence Bundle: heldout-hepc-ns5a | Arm: Paperclip MCP

**Target identifier(s) requested:** PMID 26904396
**Case notes:** Held-out outside-wheelhouse: HCV DAA.
**Synthesizer rule:** Answer the 8 evaluation prompts using ONLY the Paperclip outputs below. Do not consult external knowledge of the paper, authors, or topic. Quote bundle text to support claims. If Paperclip's outputs are wrong, missing, or contaminated (e.g., map across multiple papers), say so explicitly.

**Known Paperclip behaviors to flag:**
- map -n 1 does NOT honor the result limit; map output across multiple papers is contaminated.
- Empty /papers/<id>/supplements/ directory does not mean no supplements — may be merged into content.lines.
- Top-1 search hit is not identity proof; check that returned PMC/med/arx ID matches the target.

## Paperclip retrieval outputs (verbatim)

### heldout-hepc-ns5a__lookup_pmid.txt

```
# command: lookup pmid 26904396
# captured: 2026-05-22T00:20:02.1539126-07:00

Found 1 papers

  1. Direct anti-HCV agents
     Xingquan Zhang
     PMC4724659 · Acta Pharmaceutica Sinica. B · 2015
     https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724659/


```

### heldout-hepc-ns5a__ls.txt

```
# command: ls /papers/PMC4724659/
# captured: 2026-05-22T00:20:04.3303412-07:00

meta.json  content.lines  (65 lines)  sections/  figures/
  (read-only — use /.gxl/ for writable storage)

```

### heldout-hepc-ns5a__map_n_probe.txt

```
# command: map --from s_97706ecf -n 1 "What is the central mechanistic or empirical claim of THIS paper only?"
# captured: 2026-05-22T00:20:08.8833335-07:00

Map complete: 5/5 tasks succeeded in 1840ms
Results ID: m_47bea0fb
Full results: /.gxl/map_m_47bea0fb.txt

  [success] The Cyclophilin Inhibitor Rencofilstat Decreases HCV-induced Hepatocel  (bio_5c3736076d72)
    The paper claims that the cyclophilin inhibitor rencofilstat decreases HCV-induced hepatocellular carcinoma (HCC) in humanized mice through a mechanis
  [success] New Antiviral Agents for Hepatitis C  (PMC3292288)
    The paper claims that while the recent approval of first-generation NS3-4A protease inhibitors (telaprevir and boceprevir) in combination with pegylat
  [success] In Vitro Evaluation of Cytotoxic and Anti-HCV-4 Properties of Sofosbuv  (arx_2009.06041)
    The provided text consists only of the title; it contains no content regarding the paper's claims, methodology, or results. Therefore, this informatio
  [success] Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Ope  (PMC3687480)
    The paper claims that while first-generation direct-acting antivirals (DAAs) like telaprevir and boceprevir have improved treatment for chronic hepati
  [success] Direct anti-HCV agents  (PMC4724659)
    The central claim of this paper is that the development of second-generation direct-acting antiviral agents (DAAs) targeting HCV NS3/4A, NS5A, and NS5

Full results: /.gxl/map_m_47bea0fb.txt

```

### heldout-hepc-ns5a__search_title.txt

```
# command: search -t --all "Direct anti-HCV agents" -n 5
# captured: 2026-05-22T00:20:02.9139090-07:00

Found 5 papers  [s_ebfa8409]

  1. The Cyclophilin Inhibitor Rencofilstat Decreases HCV-induced Hepatocellular Carcinoma Independently of Its Antiviral Activity
     Winston Stauffer, Michael Bobardt, Daren Ure, Robert Foster, Philippe Gallay *
     bio_5c3736076d72 · bioRxiv · 2023-08-19
     https://doi.org/10.1101/2023.08.19.553982
     "Rencofilstat, a cyclophilin inhibitor, was studied for its effect on HCV-induced liver cancer. It significantly reduces HCC progression, independent of its antiviral activity."

  2. New Antiviral Agents for Hepatitis C
     Jean-Michel Pawlotsky
     PMC3292288 · PMC · 2012-03-01
     https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292288/
     "This paper reviews direct-acting antivirals and host-targeted agents for hepatitis C. These new treatments, used with or without interferon, are advancing clinical development."

  3. In Vitro Evaluation of Cytotoxic and Anti-HCV-4 Properties of Sofosbuvir   Encapsulated Chitosan Nanoparticles
     Samah A. Loutfy, Hosam G Abdelhady, Mostafa H. Elberry, Ahmed R. Hamed, Hussien Ahmed, M T M Hasanin...
     arx_2009.06041 · arXiv · 2020-09-13
     "Researchers investigated sofosbuvir-loaded chitosan nanoparticles for improved Hepatitis C treatment. These nanoparticles effectively eliminated HCV RNA from infected cells with no observed toxicity."

  4. Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
     Hee Bok Chae, Seon Mee Park, Sei Jin Youn
     PMC3687480 · PMC · 2013-01-01
     https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687480/
     "This paper reviews direct-acting antivirals for Hepatitis C treatment, focusing on current drugs and future drug classes. It concludes that oral drug combinations are essential for high cure rates and preventing resistance."

  5. Direct anti-HCV agents
     Xingquan Zhang
     PMC4724659 · PMC · 2015-11-24
     https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724659/
     "Direct-acting antiviral agents target HCV proteins like protease, polymerase, and NS5A. Second-generation DAAs achieve over 90% cure rates for all HCV genotypes without interferon."

[289ms, saved to s_ebfa8409]

💡 Extract data across these results with: map --from s_ebfa8409 "your question"

```

### heldout-hepc-ns5a__wc.txt

```
# command: wc /papers/PMC4724659/content.lines
# captured: 2026-05-22T00:20:05.4063121-07:00

65    3852   24665 /papers/PMC4724659/content.lines

```

